Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(19)
DRUG(2)
Dexamethasone
3 trials
phase_1phase_2
mayo-clinic
Lenalidomide
3 trials
phase_1phase_2
mayo-clinic
Ibrutinib
3 trials
phase_1phase_2
mayo-clinic
Laboratory Biomarker Analysis
3 trials
phase_1phase_2
mayo-clinic
Pharmacological Study
2 trials
phase_1
mayo-clinic
Daratumumab
2 trials
phase_2
mayo-clinic
Quality-of-Life Assessment
1 trial
phase_1
mayo-clinic
Pomalidomide
1 trial
phase_2
mayo-clinic

+3 more interventions

11 unique interventions2 categories

Analytics

Trial Phases

Phase 12
Phase 24

Trial Status

Completed4
Terminated2

Role Distribution

Principal Investigator6
PI Rate100%

Activity Timeline

Clinical Trials (6)

NCT04230304Phase 2Terminated
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Recurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Small Lymphocytic Lymphoma+2 more
PrincipalinvestigatorStart date: 2020-11-11
NCT03713294Phase 2Completed
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Refractory Plasma Cell Myeloma
PrincipalinvestigatorStart date: 2019-01-14
NCT03477539Phase 2Completed
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Plasma Cell Myeloma
PrincipalinvestigatorStart date: 2018-04-09
NCT03015792Phase 1Terminated
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
PrincipalinvestigatorStart date: 2017-03-10
NCT02697344Phase 1Completed
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
Recurrent Plasma Cell Myeloma
PrincipalinvestigatorStart date: 2016-04-14
NCT02649387Phase 2Completed
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
PrincipalinvestigatorStart date: 2016-02-08

Research Network

Collaboration Network

2 collaborators·1 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Asher Chanan-Khan, M.D.

Mayo Clinic

Moderately Similar
1 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more

Worked with same sponsors:

Mayo Clinic
Collaborated on 1 trial
Similarity Score44%

Luhua (Michael) Wang

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Similarity Score5%

PEGOURIE, MD

University Hospital, Grenoble

Related
1 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

Michel ATTAL, MD, PhD

University Hospital, Toulouse

Related
1 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

AUGEL MEUNIER, MD

CHU ST PRIEST EN JAREZ

Related
1 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

MOREL, MD

Hôpital la Pitié Salpêtrière Paris

Related
1 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

BENBRAHIM, MD

CH ORLEANS

Related
1 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

Gustavo Leone

Medical University of South Carolina, Hollings Cancer Center

Related
12 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

WETTERWALD, MD

CH DUNKERQUE

Related
1 trials

Shared therapeutic areas:

Multiple Myeloma
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT04230304Phase 2PrincipalInvestigator

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Recurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Small Lymphocytic Lymphoma+2 more
Terminated
NCT03713294Phase 2PrincipalInvestigator

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma
Completed
NCT03477539Phase 2PrincipalInvestigator

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Plasma Cell Myeloma
Completed
NCT03015792Phase 1PrincipalInvestigator

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Terminated
NCT02697344Phase 1PrincipalInvestigator

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

Recurrent Plasma Cell Myeloma
Completed
NCT02649387Phase 2PrincipalInvestigator

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Completed

All 6 trials loaded